GLOBOCAN 2022全球癌症统计数据解读OA北大核心CSTPCD
Interpretation on the global cancer statistics of GLOBOCAN 2022
2024 年 2 月国际癌症研究机构(International Agency for Research on Cancer,IARC)发布了最新的全球癌症统计数据GLOBOCAN 2022,估计了全球 185 个国家/地区的 36 种癌症发病数/率、死亡数/率等最新数据,描述了不同国家/地区和性别下的癌症负担差异,并对至 2050 年的癌症负担进行了预测.GLOBOCAN 2022 数据显示,2022 年全球估计新发癌症19 976 499 例,9 743 832 例癌症患者死亡.肺癌是全球首位常见癌症,2022 年发病例数为 2 480 675 例,占总体癌症发病的12.4%.其次是乳腺癌(11.5%)、结直肠癌(9.6%)、前列腺癌(7.3%)和胃癌(4.9%).肺癌仍是导致癌症死亡的首要原因,估计有 1 817 469 例死亡,占总体癌症死亡的 18.7%.其次是结直肠癌(9.3%)、肝癌(7.8%)、乳腺癌(6.8%)和胃癌(6.8%).基于人口统计学的预测表明,到 2050 年,全球新增癌症病例将达到 3 528.1 万例,与 2022 年相比增加 76.6%.全球癌症发病和死亡具有明显的地区和性别差异.本文对更新的数据库中主要内容进行整理并加以解读.
In February 2024,International Agency for Research on Cancer(IARC)released the latest global cancer statistics,GLOBOCAN 2022,which estimated the latest data on the number/rates of incidence and deaths of 36 types of cancer in 185 countries/regions around the world,described differences in the burden of cancer by countries/regions and gender,and provided projections of the cancer burden up to 2050.The GLOBOCAN 2022 data showed that in 2022,there were an estimated 19 976 499 new cancer cases and 9 743 832 cancer deaths worldwide.Lung cancer was the most common cancer worldwide,with 2 480 675 cases in 2022,accounting for 12.4%of all cancer cases,followed by breast cancer(11.5%),colorectal cancer(9.6%),prostate cancer(7.3%)and stomach cancer(4.9%).Lung cancer remained the leading cause of cancer deaths,with an estimated 1 817 469 deaths,accounting for 18.7%of overall cancer deaths,followed by colorectal cancer(9.3%),liver cancer(7.8%),breast cancer(6.8%)and stomach cancer(6.8%).Demographics-based projections indicate that by 2050,there will be 35.28 million new cancer cases globally,a 76.6%increase from 2022 levels.There are significant regional and gender differences in global cancer incidence and mortality.In this article,the main contents of the updated database are sorted out and interpreted.
曹梦迪;陈万青
国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院 癌症早诊早治办公室,北京 100021
GLOBOCAN 2022癌症发病死亡全球估计
GLOBOCAN 2022CancerIncidenceMortalityGlobal estimates
《中国医学前沿杂志(电子版)》 2024 (006)
1-5 / 5
评论